Although the effectiveness of CFTR modulators is encouraging with regard to the improved prognosis of most patients, the great pathophysiologic diversity of CF remains unaddressed in about 10% of PwCF who carry either minimal function mutations that are not known to be responsive to HEMT or unknown genotypes. The gene discussed is CFTR; the disease is cystic fibrosis.